These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 25443916)

  • 1. Evaluation of the prognostic significance of altered mammalian target of rapamycin pathway biomarkers in upper tract urothelial carcinoma.
    Bagrodia A; Krabbe LM; Gayed BA; Kapur P; Bernstein I; Xie XJ; Wood CG; Karam JA; Weizer AZ; Raman JD; Remzi M; Rioux-Leclerq N; Haitel A; Roscigno M; Bolenz C; Bensalah K; Sagalowsky AI; Shariat SF; Lotan Y; Margulis V
    Urology; 2014 Nov; 84(5):1134-40. PubMed ID: 25443916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dysregulation of mammalian target of rapamycin pathway in upper tract urothelial carcinoma.
    Munari E; Fujita K; Faraj S; Chaux A; Gonzalez-Roibon N; Hicks J; Meeker A; Nonomura N; Netto GJ
    Hum Pathol; 2013 Dec; 44(12):2668-76. PubMed ID: 24074531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cumulative number of altered biomarkers in mammalian target of rapamycin pathway is an independent predictor of outcome in patients with clear cell renal cell carcinoma.
    Darwish OM; Kapur P; Youssef RF; Bagrodia A; Belsante M; Alhalabi F; Sagalowsky AI; Lotan Y; Margulis V
    Urology; 2013 Mar; 81(3):581-6. PubMed ID: 23290145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma.
    Cha EK; Shariat SF; Kormaksson M; Novara G; Chromecki TF; Scherr DS; Lotan Y; Raman JD; Kassouf W; Zigeuner R; Remzi M; Bensalah K; Weizer A; Kikuchi E; Bolenz C; Roscigno M; Koppie TM; Ng CK; Fritsche HM; Matsumoto K; Walton TJ; Ehdaie B; Tritschler S; Fajkovic H; Martínez-Salamanca JI; Pycha A; Langner C; Ficarra V; Patard JJ; Montorsi F; Wood CG; Karakiewicz PI; Margulis V
    Eur Urol; 2012 Apr; 61(4):818-25. PubMed ID: 22284969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective analysis of Ki-67 as an independent predictor of oncologic outcomes in patients with high grade upper tract urothelial carcinoma.
    Krabbe LM; Bagrodia A; Lotan Y; Gayed BA; Darwish OM; Youssef RF; John G; Harrow B; Jacobs C; Gaitonde M; Sagalowsky AI; Shariat SF; Kapur P; Margulis V
    J Urol; 2014 Jan; 191(1):28-34. PubMed ID: 23871758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma.
    Haddad AQ; Kapur P; Singla N; Raman JD; Then MT; Nuhn P; Buchner A; Bastian P; Seitz C; Shariat SF; Bensalah K; Rioux-Leclercq N; Sagalowsky A; Lotan Y; Margulis V
    Cancer; 2015 Jan; 121(1):43-50. PubMed ID: 25186283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of tumor size on recurrence-free survival of upper tract urothelial carcinoma following surgical resection.
    Espiritu PN; Sverrisson EF; Sexton WJ; Pow-Sang JM; Poch MA; Dhillon J; Spiess PE
    Urol Oncol; 2014 Jul; 32(5):619-24. PubMed ID: 24495448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of preoperative anemia on oncologic outcomes of upper tract urothelial carcinoma treated with radical nephroureterectomy.
    Rink M; Sharifi N; Fritsche HM; Aziz A; Miller F; Kluth LA; Ngamsri T; Dahlem R; Chun FK; Shariat SF; Stenzl A; Fisch M; Gakis G
    J Urol; 2014 Feb; 191(2):316-22. PubMed ID: 24036235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-reactive protein: a biomarker of survival in patients with localized upper tract urothelial carcinoma treated with radical nephroureterectomy.
    Obata J; Kikuchi E; Tanaka N; Matsumoto K; Hayakawa N; Ide H; Miyajima A; Nakagawa K; Oya M
    Urol Oncol; 2013 Nov; 31(8):1725-30. PubMed ID: 23141922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
    Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
    Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High levels of phosphatase and tensin homolog expression are associated with tumor progression, tumor recurrence, and systemic metastases in pT1 urothelial carcinoma of the bladder: a tissue microarray study of 156 patients treated by transurethral resection.
    Chaux A; Compérat E; Varinot J; Hicks J; Lecksell K; Solus J; Netto GJ
    Urology; 2013 Jan; 81(1):116-22. PubMed ID: 23273076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy.
    Lotan Y; Bagrodia A; Passoni N; Rachakonda V; Kapur P; Arriaga Y; Bolenz C; Margulis V; Raj GV; Sagalowsky AI; Shariat SF
    Eur Urol; 2013 Sep; 64(3):465-71. PubMed ID: 23571005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Perioperative Allogenic Blood Transfusion on Survival After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma.
    Rink M; Soave A; Dahlem R; Aziz A; Al-Sayed F; Peine S; Engel O; Kluth LA; Stenzl A; Burger M; Shariat SF; Fisch M; Fritsche HM; Gakis G
    Clin Genitourin Cancer; 2016 Feb; 14(1):96-104. PubMed ID: 26506908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The predictive value of positive urine cytology for outcomes following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma: a multi-institutional study.
    Tanaka N; Kikuchi E; Kanao K; Matsumoto K; Shirotake S; Kobayashi H; Miyazaki Y; Ide H; Obata J; Hoshino K; Hayakawa N; Kosaka T; Oyama M; Miyajima A; Momma T; Nakagawa K; Jinzaki M; Nakajima Y; Oya M
    Urol Oncol; 2014 Jan; 32(1):48.e19-26. PubMed ID: 24055429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic significance of vasohibin-1 expression in patients with upper urinary tract urothelial carcinoma.
    Miyazaki Y; Kosaka T; Mikami S; Kikuchi E; Tanaka N; Maeda T; Ishida M; Miyajima A; Nakagawa K; Okada Y; Sato Y; Oya M
    Clin Cancer Res; 2012 Aug; 18(15):4145-53. PubMed ID: 22675166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer.
    Fahmy M; Mansure JJ; Brimo F; Yafi FA; Segal R; Althunayan A; Hicks J; Meeker A; Netto G; Kassouf W
    Hum Pathol; 2013 Sep; 44(9):1766-72. PubMed ID: 23623586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma.
    Fritsche HM; Novara G; Burger M; Gupta A; Matsumoto K; Kassouf W; Sircar K; Zattoni F; Walton T; Tritschler S; Baba S; Bastian PJ; Martínez-Salamanca JI; Seitz C; Otto W; Wieland WF; Karakiewicz PI; Ficarra V; Hartmann A; Shariat SF
    Urol Oncol; 2012 Sep; 30(5):666-72. PubMed ID: 20933445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma.
    Li SH; Huang EY; Lu HI; Huang WT; Yen CC; Huang WC; Chen CH
    J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1352-9, 1359.e1. PubMed ID: 22841170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urothelial carcinoma at the uretero-enteric junction: multi-center evaluation of oncologic outcomes after radical nephroureterectomy.
    Youssef RF; Shariat SF; Lotan Y; Cost N; Wood CG; Sagalowsky AI; Zigeuner R; Langner C; Chromecki TF; Montorsi F; Bolenz C; Margulis V
    Urol Oncol; 2013 Jul; 31(5):676-81. PubMed ID: 21704538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.